Joseph Shanklin, MD
Psychiatry · Clearwater, FLNPI 1356453021
Payments from drug & device makers
Across 381 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$839
- Vanda Pharmaceuticals Inc.$765
- Axsome Therapeutics, Inc.$651
- Jazz Pharmaceuticals Inc.$650
- plus $4K from 27 others
What the payments were for
- Consulting fees$1502%
- Food & beverage$8,44196%
- Education$2002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 42 | $1,144 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $1,102 |
| AbbVie(2 entities) | 45 | $839 |
| Vanda Pharmaceuticals Inc. | 32 | $765 |
| Axsome Therapeutics, Inc. | 23 | $651 |
| Jazz Pharmaceuticals Inc. | 20 | $650 |
| Lundbeck LLC | 22 | $428 |
| Sunovion Pharmaceuticals Inc. | 23 | $395 |
| Neurocrine Biosciences, Inc. | 11 | $355 |
| Harmony Biosciences LLC | 8 | $319 |
| Ironshore Pharmaceuticals Inc. | 14 | $290 |
| Alkermes, Inc. | 13 | $244 |
| Teva Pharmaceuticals USA, Inc. | 7 | $238 |
| Johnson & Johnson | 9 | $200 |
| Merck | 8 | $154 |
| Corium, LLC | 7 | $153 |
| E.r. Squibb & Sons, L.L.C. | 6 | $134 |
| Bausch Health US, LLC | 7 | $120 |
| Idorsia Pharmaceuticals US Inc | 6 | $118 |
| TMS Neurohealth Centers Inc. | 4 | $73 |
| Shire North American Group Inc | 3 | $54 |
| Noven Therapeutics, LLC | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Eisai Inc. | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Adlon Therapeutics L.p. | 2 | $32 |
| Almatica Pharma LLC | 2 | $31 |
| Vertical Pharmaceuticals, LLC | 2 | $31 |
| Neos Therapeutics, LP | 2 | $30 |
| Brainsway USA Inc | 1 | $23 |
| Neuronetics, Inc. | 1 | $22 |
| Tris Pharma Inc | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,791 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 11 | $221,094 |
| Austedo XrDeutetrabenazine | 17 | $181,428 |
| RexultiBrexpiprazole | 49 | $127,539 |
| TrintellixVortioxetine Hydrobromide | 47 | $58,557 |
| FetzimaLevomilnacipran Hcl | 19 | $29,927 |
| Lurasidone Hcl | 17 | $10,847 |
| DayvigoLemborexant | 18 | $7,757 |
| Bupropion XlBupropion Hcl | 205 | $6,721 |
| Vilazodone Hcl | 45 | $4,397 |
| Lisdexamfetamine Dimesylate | 15 | $3,851 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 107 | $3,327 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 29 | $2,815 |
| Alprazolam | 136 | $2,524 |
| Modafinil | 22 | $2,459 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 77 | $2,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $238 | $181,42817 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,144 | $127,53949 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $41 | $58,55747 claims |
| AbbVieFetzima | $839 | $29,92719 claims |
| Eisai Inc.Dayvigo | $39 | $7,75718 claims |
| Almatica Pharma LLCSertraline Hcl | $31 | $62147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Clearwater
- Michelle ScargleClearwater$926K
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.